LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Malignant Bowel Obstruction.

    Fackche, Nadege T / Johnston, Fabian M

    Advances in surgery

    2021  Volume 55, Page(s) 35–48

    MeSH term(s) Humans ; Intestinal Obstruction/diagnostic imaging ; Intestinal Obstruction/etiology ; Intestinal Obstruction/surgery ; Palliative Care
    Language English
    Publishing date 2021-07-06
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 411889-3
    ISSN 1878-0555 ; 0065-3411
    ISSN (online) 1878-0555
    ISSN 0065-3411
    DOI 10.1016/j.yasu.2021.05.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative.

    Fackche, Nadege T / Schmocker, Ryan K / Nudotor, Richard / Kubi, Boateng / Cloyd, Jordan M / Grotz, Travis E / Fournier, Keith F / Dineen, Sean P / Veerapong, Jula / Baumgartner, Joel M / Clarke, Callisia N / Patel, Sameer H / Wilson, Gregory C / Lambert, Laura A / Pokrzywa, Courtney / Abbott, Daniel E / Lee, Byrne / Staley, Charles A / Zaidi, Mohammad Y /
    Johnston, Fabian M / Greer, Jonathan B

    Annals of surgical oncology

    2024  Volume 31, Issue 5, Page(s) 3314–3324

    Abstract: Introduction: Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor ... ...

    Abstract Introduction: Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC.
    Methods: Patients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified. Progression-free survival (PFS), defined as disease progression or recurrence, was the primary outcome.
    Results: In 279 patients who met inclusion criteria, the rate of disease progression was 63.8%, with a median PFS of 11 months (interquartile range [IQR] 5-20). Elevated CA 19-9 was associated with dismal PFS at 2 years (8.9% elevated vs. 30% not elevated, p < 0.01). In 113 patients who underwent upfront CRS/HIPEC, CA 19-9 emerged as the sole tumor marker independently predictive of worse PFS (hazard ratio [HR] 2.88, p = 0.048). In the subgroup of patients who had received neoadjuvant therapy (NAT), no variable was independently predictive of PFS. CA 19-9 levels over 37 U/ml were highly specific for accelerated disease progression after CRS/HIPEC. Lastly, there was no association between PFS and elevated CEA or CA 125.
    Conclusions: Elevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association.
    MeSH term(s) Humans ; Hyperthermic Intraperitoneal Chemotherapy ; Peritoneal Neoplasms/secondary ; Colorectal Neoplasms/pathology ; Cytoreduction Surgical Procedures ; Hyperthermia, Induced ; Chemotherapy, Cancer, Regional Perfusion ; Disease Progression ; Biomarkers, Tumor ; Combined Modality Therapy ; Survival Rate ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Retrospective Studies
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2024-02-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-024-14890-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways.

    Eng, Oliver S / Blakely, Andrew M / Lafaro, Kelly J / Fournier, Keith F / Fackche, Nadege T / Johnston, Fabian M / Dineen, Sean / Powers, Benjamin / Hendrix, Ryan / Lambert, Laura A / Ronnekleiv-Kelly, Sean / Walle, Kara Vande / Grotz, Travis E / Leiting, Jennifer L / Patel, Sameer H / Dhar, Vikrom K / Baumgartner, Joel M / Lowy, Andrew M / Clarke, Callisia N /
    Mogal, Harveshp / Zaidi, Mohammad Y / Staley, Charles A / Kimbrough, Charles / Cloyd, Jordan M / Lee, Byrne / Raoof, Mustafa

    Journal of surgical oncology

    2020  Volume 122, Issue 5, Page(s) 980–985

    Abstract: Background: Variations in care have been demonstrated both within and among institutions in many clinical settings. By standardizing perioperative practices, Enhanced Recovery After Surgery (ERAS) pathways reduce variation in perioperative care. We ... ...

    Abstract Background: Variations in care have been demonstrated both within and among institutions in many clinical settings. By standardizing perioperative practices, Enhanced Recovery After Surgery (ERAS) pathways reduce variation in perioperative care. We sought to characterize the variation in cytoreductive surgery (CRS)/heated intraperitoneal chemotherapy (HIPEC) perioperative practices among experienced US medical centers.
    Methods: Data from the US HIPEC Collaborative represents a retrospective multi-institutional cohort study of CRS and CRS/HIPEC procedures performed from 12 major academic institutions. Patient characteristics and perioperative practices were reported and compared. Institutional variation was analyzed using hierarchical mixed-effects linear (continuous outcomes) or logistic (binary outcomes) regression models.
    Results: A total of 2372 operations were included. CRS/HIPEC was performed most commonly for appendiceal histologies (64.2%). The rate of complications (overall 56.3%, range: 31.8-70.9) and readmissions (overall 20.6%, range: 8.9-33.3) varied by institution (P < .001). Institution-level variation in perioperative practice patterns existed among measured ERAS pathway process/outcomes (P < .001). The percentages of variation with each process/outcome measure attributable solely to institutional practices ranged from 0.6% to 66.6%.
    Conclusions: Significant variation exists in the perioperative care of patients undergoing CRS/HIPEC at major US academic institutions. These findings provide a strong rationale for the investigation of best practices in CRS/HIPEC patients.
    MeSH term(s) Cohort Studies ; Cytoreduction Surgical Procedures/methods ; Cytoreduction Surgical Procedures/standards ; Cytoreduction Surgical Procedures/statistics & numerical data ; Enhanced Recovery After Surgery ; Female ; Humans ; Hyperthermic Intraperitoneal Chemotherapy/methods ; Hyperthermic Intraperitoneal Chemotherapy/statistics & numerical data ; Male ; Middle Aged ; Neoplasms/drug therapy ; Neoplasms/surgery ; Neoplasms/therapy ; Retrospective Studies ; Treatment Outcome
    Language English
    Publishing date 2020-07-05
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 82063-5
    ISSN 1096-9098 ; 0022-4790
    ISSN (online) 1096-9098
    ISSN 0022-4790
    DOI 10.1002/jso.26099
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top